Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.

Pelegrí, Amadeu; Calvo, Lourdes; Antón, Antonio; Mayordomo, José I; Florián, Jesus; Vásquez, Santiago; Arcusa, Angels; Martín-Richard, Marta; Bayo, José L; Carrasco, Eva; Virizuela, Javier

Pelegrí, Amadeu; Calvo, Lourdes; Antón, Antonio; Mayordomo, José I; Florián, Jesus; Vásquez, Santiago; Arcusa, Angels; Martín-Richard, Marta; Bayo, José L; Carrasco, Eva; Virizuela, Javier.

Affiliation

Pelegrí A; Hospital Universitari Sant Joan, Reus, Spain. apelegri@grupsagessa.com

Clin Breast Cancer ; 6(5): 433-8, 2005 Dec.

Article in En | MEDLINE | ID: mdl-16381627

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Deoxycytidine/administration & dosage; Deoxycytidine/adverse effects; Deoxycytidine/analogs & derivatives; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia/chemically induced; Taxoids/administration & dosage; Taxoids/adverse effects; Gemcitabine

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Year: 2005 Type: Article

Search on Google

XML

PubMed Links